Pfizer Inc. $PFE Shares Sold by Oak Hill Wealth Advisors LLC

Oak Hill Wealth Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the second quarter, HoldingsChannel.com reports. The firm owned 8,142 shares of the biopharmaceutical company’s stock after selling 511 shares during the period. Oak Hill Wealth Advisors LLC’s holdings in Pfizer were worth $209,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in PFE. Bessemer Group Inc. increased its position in shares of Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after acquiring an additional 13,228 shares during the period. Capital Advisors Inc. OK grew its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the 1st quarter valued at about $8,283,000. Westbourne Investments Inc. acquired a new stake in shares of Pfizer during the 1st quarter valued at about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in shares of Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.37 on Friday. The company has a 50-day simple moving average of $24.67 and a 200-day simple moving average of $24.15. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.